IL-32 mRNA levels have been found to increase in tumoral samples, and, when cultured, tumor viability has been impaired by adding anti-IL-32 antibodies, confirming the potential effect of IL-32 on MF and SS viability and progression [86,232]. This evidence concerns the gene IL32 and neoplasm.